Part 1: Device Selection and Patient Assessment

1. Overview of Central Venous Access Devices in Oncology

1.1 Rationale for Central Venous Access in Cancer Patients

The majority of systemic anticancer regimens require central venous access for safe and effective administration. Vesicant chemotherapy agents — including anthracyclines (doxorubicin, epirubicin), vinca alkaloids (vincristine, vinblastine, vinorelbine), nitrogen mustards, and taxanes — carry significant risk of tissue necrosis if extravasated through peripheral veins.¹² Beyond vesicant risk, central venous access is indicated for:

• Continuous infusion regimens (e.g., 5-fluorouracil over 46–48 hours, cisplatin hydration protocols)
• Hyperosmolar solutions including parenteral nutrition (osmolarity >900 mOsm/L)
• Infusions with extreme pH values (pH <5 or >9)
• Regimens requiring simultaneous administration of multiple incompatible agents
• Frequent blood sampling requirements during intensive treatment phases
• Blood product transfusion support during myelosuppressive therapy
• Prolonged treatment courses spanning months to years across multiple lines of therapy¹³⁴

1.2 Guiding Principles of Device Selection

Device selection in oncology should follow the principle of minimal intervention: the least invasive device with the smallest diameter and fewest lumens necessary to safely complete the prescribed therapy for its anticipated duration.⁴⁵ This principle must be balanced against the unique demands of oncology treatment, where long duration, vesicant administration, and immunosuppression often necessitate central venous access from the outset.

Selection decisions should be collaborative, involving the oncology team, vascular access specialists, the patient, and caregivers. Key considerations include:³⁴⁵

1. Prescribed treatment regimen and infusate characteristics
2. Anticipated total duration of therapy (weeks, months, or years)
3. Frequency of access (daily, weekly, cyclical)
4. Need for simultaneous multi-lumen access
5. Patient’s vascular anatomy and history of prior vascular access
6. Coagulation status and thrombotic risk profile
7. Immunologic status and infection risk
8. Patient preference, body habitus, and lifestyle considerations
9. Availability of care resources for device maintenance

2. CVAD Types: Characteristics and Oncology Indications

2.1 Implanted Vascular Access Ports (Totally Implantable Venous Access Devices)

Description: A port consists of a subcutaneously implanted reservoir (portal body) connected to a silicone or polyurethane catheter whose tip is positioned at the cavoatrial junction (CAJ). The device is accessed percutaneously through the overlying skin using a noncoring (Huber) needle. Ports may be placed in the chest (infraclavicular fossa) or upper arm. Single- and dual-lumen configurations are available. Power-injectable ports allow high-pressure contrast injection for radiologic imaging.²⁶

Oncology Indications:

Advantages in Oncology:

• Lower infection rates compared to PICCs and tunneled catheters in oncology populations⁸⁹¹⁰
• Lower thrombosis rates compared to PICCs in cancer patients⁷⁸¹¹
• Minimal impact on daily activities when deaccessed
• Extended dwell time capability (months to years)
• Maintenance flushing intervals of every 4 to 12 weeks when not in active use (some evidence supports extending to every 3 months)⁶
• Reduced body image disturbance compared to externalized devices
• Appropriate for power injection when labeled accordingly

Limitations:

• Requires a surgical or interventional radiology procedure for both placement and removal
• Access requires trained clinician using noncoring needle technique
• Potential for needle dislodgement causing vesicant extravasation into subcutaneous tissue
• Port pocket infection or erosion may require surgical intervention
• Not optimal for continuous infusion regimens requiring prolonged needle dwell time
• Septum integrity degrades after approximately 1,000–2,000 punctures (varies by manufacturer)⁶

2.2 Peripherally Inserted Central Catheters (PICCs)

Description: PICCs are inserted into peripheral veins of the upper arm (basilic, brachial, or cephalic veins) with the catheter tip advanced to the CAJ. Available in single-, double-, and triple-lumen configurations. May be valved or non-valved, and some models are power-injectable. Typically inserted by vascular access specialists or interventional radiologists using ultrasound guidance and modified Seldinger technique.⁴⁵

Oncology Indications:

Advantages in Oncology:

• Bedside insertion without general anesthesia or operating room
• Suitable for continuous and intermittent infusion
• Multi-lumen options for complex regimens
• Can be removed at bedside when no longer needed
• Power-injectable models available

Limitations:

• Higher thrombosis rates than ports in oncology patients, particularly in patients with active cancer receiving chemotherapy⁷⁸¹¹
• Higher infection rates than ports in several oncology studies⁸⁹
• External catheter requires daily maintenance and limits some activities
• Restriction of upper extremity activities (blood pressure measurement, venipuncture on ipsilateral arm)
• Body image concerns from visible externalized catheter
• Higher catheter-to-vessel ratio in smaller arm veins compared to centrally placed devices

2.3 Tunneled Central Venous Catheters

Description: Tunneled catheters (e.g., Hickman, Broviac, Groshong) are surgically placed via the internal jugular or subclavian vein. The catheter is tunneled subcutaneously from the venotomy site to an exit site on the anterior chest wall, with a Dacron cuff positioned within the subcutaneous tunnel to promote tissue ingrowth and provide mechanical stabilization and a barrier against ascending skin organisms. Available in single-, double-, and triple-lumen configurations.¹²

Oncology Indications:

Advantages in Oncology:

• Multiple lumens allow simultaneous administration of incompatible agents
• Large internal diameter supports rapid infusion and apheresis
• Subcutaneous cuff provides stabilization and infection barrier
• Continuous access without repeated needle punctures
• Suitable for all infusion therapies

Limitations:

• Requires surgical placement and removal
• Higher infection rates than ports in most oncology studies⁸⁹
• External catheter requires daily care and limits bathing
• Risk of accidental dislodgement
• Greater body image impact than ports
• Catheter damage (cracking, breakage) from repeated clamping

2.4 Nontunneled Central Venous Catheters

Description: Nontunneled CVCs are percutaneously inserted into the internal jugular, subclavian, or femoral vein with the catheter tip positioned at the CAJ. They lack a subcutaneous cuff or tunnel. Typically multi-lumen (double or triple).⁴

Oncology Indications:

Limitations for Oncology:

• Not appropriate for long-term use (typically <14 days)
• Highest infection risk among CVAD types⁹
• No mechanical stabilization (cuff or tunnel)
• Subclavian site should be avoided in patients with chronic kidney disease or anticipated need for arteriovenous fistula creation⁴⁵

3. Comparative Device Selection in Oncology

3.1 Head-to-Head Evidence

A landmark multicenter randomized controlled trial (the CAVA trial) compared PICCs, ports, and tunneled Hickman catheters for systemic anticancer therapy delivery. Key findings included:¹¹

• Complication rates: Ports demonstrated the lowest overall complication rate. PICCs and Hickman catheters showed higher rates of device-related complications including infection and thrombosis.
• Thrombosis: PICCs were associated with the highest deep vein thrombosis rate among the three device types in oncology patients.
• Infection: Ports had the lowest catheter-related bloodstream infection rate.
• Patient satisfaction: Ports received the highest patient satisfaction scores, attributed to minimal interference with daily activities and body image.
• Cost-effectiveness: Ports were cost-effective when expected use duration exceeded approximately 3 months.

3.2 Device Selection Algorithm for Oncology

The following algorithm integrates evidence from multiple professional society guidelines:¹³²⁴⁵

Step 1: Assess Treatment Plan

• What agents will be administered? (vesicant, irritant, non-vesicant)
• What is the planned total treatment duration?
• How frequently will access be required?
• How many simultaneous lumens are needed?
• Will continuous infusion be required?

Step 2: Assess Patient Factors

• Vascular anatomy and access history
• Coagulation status and thrombotic risk
• Immune function and neutropenia risk
• Body habitus and chest anatomy
• Patient preference and lifestyle considerations
• Home care resources and self-management capability

Step 3: Match Device to Clinical Need

3.3 Single-Lumen Versus Multi-Lumen Selection

The minimum number of lumens necessary to accommodate the prescribed therapy should be selected. Evidence demonstrates that each additional lumen increases the risk of both infection and thrombosis.⁴⁵⁷

• Single lumen: Adequate for most intermittent chemotherapy regimens, single-agent continuous infusions, and routine blood sampling
• Double lumen: Required when simultaneous administration of two incompatible agents is necessary or when continuous infusion plus intermittent bolus dosing occurs concurrently
• Triple lumen: Reserved for intensive care settings, stem cell transplant, or acute leukemia induction with simultaneous multi-drug infusion, TPN, and blood product requirements

4. Patient Assessment for CVAD Selection in Oncology

4.1 Vascular Assessment

A systematic vascular assessment is essential before CVAD placement in oncology patients, who frequently present with compromised venous anatomy from prior treatments:⁴⁵

Assessment Components:

1. Prior vascular access history: Document all previous CVAD types, insertion sites, dwell times, and complications including thrombosis, infection, and mechanical failure. Prior catheter-associated thrombosis narrows future access options and may necessitate imaging before subsequent placement.

2. Chemotherapy-related vessel damage: Prior peripheral chemotherapy administration, particularly of vesicant agents, may cause sclerosis, fibrosis, and thrombosis of peripheral veins. Vessel assessment should include ultrasound evaluation when peripheral vein damage is suspected.

3. Radiation effects: Chest wall radiation (particularly for breast cancer, lymphoma, or lung cancer) can cause fibrosis and stenosis of subclavian and brachiocephalic veins. Radiation to the neck may affect jugular venous anatomy. Imaging may be warranted before attempted placement on the irradiated side.¹²

4. Tumor-related venous compression: Mediastinal masses, superior vena cava (SVC) syndrome, and lymphadenopathy may distort or obstruct central venous anatomy. Contrast-enhanced CT or venography should be obtained when SVC obstruction is suspected or known.

5. Bilateral upper extremity assessment: Evaluate both arms for vein size, depth, and patency using ultrasound. Assess for signs of prior or current thrombosis (limb edema, venous collaterals, erythema).

6. Mastectomy and lymphedema considerations: Ipsilateral CVAD placement should be avoided in extremities affected by lymphedema or in patients who have undergone axillary lymph node dissection, due to increased infection and thrombosis risk and potential worsening of lymphedema.¹⁵

4.2 Thrombotic Risk Assessment

Cancer patients face elevated thrombotic risk that must be factored into CVAD selection and management:⁷¹³

Cancer-Specific Thrombotic Risk Factors:

Risk Assessment Tools:

The Khorana score is validated for predicting VTE in ambulatory cancer patients initiating chemotherapy, though it was not specifically developed for catheter-associated thrombosis prediction. The Michigan Risk Score was developed specifically for PICC-associated thrombosis and incorporates both patient and device factors.⁷¹³

Implications for Device Selection:

• In patients with high thrombotic risk, implanted ports are preferred over PICCs for long-term access, based on lower thrombosis rates in the oncology population⁷⁸¹¹
• When PICCs are used, single-lumen devices with optimal catheter-to-vessel ratio (not exceeding 45%) should be selected⁷
• Femoral insertion sites carry the highest thrombotic risk and should be avoided when possible⁵
• The role of pharmacologic thromboprophylaxis specifically for catheter-associated thrombosis prevention in cancer patients remains under investigation; current evidence supports VTE prophylaxis for cancer patients with CVADs without increased major bleeding risk¹³

4.3 Infection Risk Assessment

Oncology patients face elevated central line-associated bloodstream infection (CLABSI) risk due to immunosuppression:¹⁹¹⁴

Oncology-Specific Infection Risk Factors:

• Neutropenia (absolute neutrophil count <500 cells/mm³)
• Prolonged neutropenia (>7 days)
• Mucositis and breakdown of gastrointestinal mucosal barriers
• Lymphopenia from chemotherapy or immunotherapy
• Hematologic malignancies (highest CLABSI rates)
• Stem cell transplant recipients
• Total parenteral nutrition administration
• High-dose corticosteroid therapy
• Prolonged hospitalization

Implications for Device Selection:

• Implanted ports carry the lowest infection risk among CVADs in oncology and should be preferred when clinically appropriate⁸⁹
• Antimicrobial-impregnated catheters (chlorhexidine/silver sulfadiazine or minocycline/rifampin) may be considered for short-term nontunneled CVCs in high-risk patients, though evidence in long-term oncology CVADs is limited⁹¹⁴
• All CVADs should be removed promptly when no longer clinically indicated to minimize cumulative infection risk

4.4 Coagulation Assessment

Thrombocytopenia and coagulopathy are common in oncology patients and affect both CVAD placement and maintenance:¹²

Pre-Insertion Coagulation Assessment:

Recommendations by Guideline Panels:

The professional oncology society recommends that implanted ports and tunneled catheters can be safely placed in patients with platelet counts of 50,000/µL or greater without prophylactic platelet transfusion. For lower counts, periprocedural platelet transfusion should be considered. PICCs have been placed safely in thrombocytopenic patients with platelet counts as low as 20,000/µL given the compressible nature of the insertion site, though individual institutional protocols vary.¹²

4.5 Assessment of Chest Anatomy and Prior Surgery

Specific Oncology Considerations:

• Prior mastectomy: Avoid ipsilateral CVAD placement due to altered lymphatic drainage, infection risk, and potential for lymphedema exacerbation¹⁵
• Bilateral mastectomy: Device placement may require individualized assessment; chest ports remain feasible with careful planning
• Prior chest radiation: Fibrosis may cause subclavian or brachiocephalic stenosis; contralateral placement preferred when possible; venography may be warranted¹²
• Mediastinal masses: May distort SVC anatomy; imaging recommended before insertion
• Prior neck dissection: Avoid ipsilateral jugular approach
• Pacemakers or implantable defibrillators: Coordinate placement to avoid device-device interference; contralateral placement typically preferred

5. Vein Selection in Oncology Patients

5.1 Upper Extremity Vein Selection for PICCs

The basilic vein is the preferred insertion site for PICCs in oncology patients due to its larger diameter, straighter course, and location away from critical neurovascular structures. The brachial veins represent an acceptable alternative, though they course adjacent to the brachial artery and median nerve. The cephalic vein is the least preferred due to its smaller caliber, more tortuous course, and a sharp angle at its junction with the axillary vein, which increases risk of malposition and may limit catheter advancement.⁴⁵

Ultrasound-Guided Vessel Assessment Before PICC Insertion:

1. Measure vein diameter in cross-section
2. Calculate anticipated catheter-to-vessel ratio (target: ≤45%)⁷
3. Assess vein compressibility (rule out existing thrombosis)
4. Evaluate vein depth from skin surface
5. Identify accompanying arteries and nerves
6. Assess both arms and compare findings
7. Document all measurements for procedural planning

5.2 Central Vein Selection for Tunneled Catheters and Ports

Internal Jugular Vein:

• Preferred for most tunneled catheters and chest ports
• Lower risk of pneumothorax compared to subclavian approach
• Right-sided placement preferred due to more direct course to the SVC
• Ultrasound-guided cannulation is the standard of care⁴⁵

Subclavian Vein:

• Traditional approach for port placement; remains widely used
• Associated with lower thrombosis rates compared to jugular and femoral approaches in intensive care settings⁵
• Higher risk of pneumothorax and, in the event of arterial puncture, inability to apply direct compression
• Should be avoided in patients with chronic kidney disease requiring vein preservation for future hemodialysis access
• Risk of pinch-off syndrome when catheter passes between the clavicle and first rib⁵

Femoral Vein:

• Reserved for situations where upper body access is not feasible (e.g., SVC syndrome, bilateral upper extremity thrombosis)
• Highest thrombosis and infection risk⁵⁹
• Transhepatic and translumbar approaches are available as last-resort alternatives in patients with exhausted conventional access sites

5.3 Laterality Considerations in Oncology

6. Special Population Considerations for Device Selection

6.1 Pediatric Oncology

Implanted ports are the preferred vascular access device for children with cancer requiring long-term treatment, based on evidence of lower thrombosis and infection rates compared to tunneled catheters and PICCs in this population.⁷⁸ Key considerations include:

• Port size: Pediatric-specific low-profile ports are available for smaller children
• Placement site: Chest ports are standard; arm ports may be considered in older adolescents
• Catheter size: Smallest diameter catheter that accommodates the treatment plan
• Pain management: Topical anesthetic (EMLA cream or LMX) applied 30–60 minutes before port access is standard practice to minimize procedural distress
• Growth considerations: Catheter tip position may change as the child grows, requiring periodic radiographic surveillance and potential device exchange⁶
• PICCs in children: PICCs are associated with significantly higher catheter-related VTE risk than tunneled catheters or ports in pediatric patients; repeated PICC insertions in the same extremity should be avoided due to cumulative thrombotic risk⁷

6.2 Elderly Oncology Patients

Device selection in elderly patients should account for:

• Increased skin fragility and reduced subcutaneous tissue
• Higher incidence of cardiac disease and pacemaker/defibrillator presence
• Potential for cognitive impairment affecting self-management capability
• Greater susceptibility to catheter-related bloodstream infection
• Consideration of performance status and prognosis in device selection
• Ports are generally well-tolerated and reduce maintenance burden for patients with limited mobility or cognitive changes

6.3 Patients on Anticoagulation Therapy

Many oncology patients receive therapeutic anticoagulation for cancer-associated VTE. Device selection considerations include:

• PICCs may be inserted without interruption of anticoagulation at most institutions, given the compressible insertion site
• Port placement and tunneled catheter insertion typically require coordination with anticoagulation management (e.g., holding low-molecular-weight heparin for 24 hours, or warfarin to achieve INR ≤1.5)
• Direct oral anticoagulants should be held according to agent-specific pharmacokinetics and institutional protocols
• Device removal on anticoagulation requires similar planning

6.4 Patients with Renal Insufficiency

For oncology patients with concurrent chronic kidney disease:

• Subclavian vein access should be avoided to preserve vessels for potential future dialysis access⁴⁵
• PICCs should be used cautiously, as they may cause subclinical upper extremity thrombosis that compromises future AV fistula creation
• Internal jugular approach is preferred for tunneled catheters
• Nephrology consultation is recommended before CVAD placement in patients with eGFR <30 mL/min/1.73 m²

6.5 Patients with Superior Vena Cava Syndrome

Patients with SVC obstruction from mediastinal tumor or thrombosis require individualized vascular access planning:

• Imaging (contrast-enhanced CT or venography) should precede CVAD placement
• Femoral, transhepatic, or translumbar approaches may be necessary
• Interventional radiology consultation is essential
• SVC stenting may restore access to conventional upper body sites
• Collateral venous pathways should be assessed for potential catheter routes

References